Next, EphB4 showed high positive rates in 100% of oral cancer, 92% of pharyngeal cancer, 83% of breast cancer, 94% of esophageal cancer, 79% of lung cancer, 100% of gastric cancer (including 89% of early gastric cancer), 80% of biliary tract cancer, 75% of pancreatic cancer, 70% of hepatocellular carcinoma, 93% of colorectal cancer, 83% of ovarian cancer, 86% of uterine cancer, 89% of hepatoblastoma, and 65% of melanoma. Here, EPHB4 is linked to hepatocellular carcinoma.